QURE
Price
$15.87
Change
+$0.08 (+0.51%)
Updated
Jan 31, 01:23 PM (EDT)
Capitalization
814.39M
31 days until earnings call
ZVRA
Price
$8.10
Change
+$0.08 (+1.00%)
Updated
Jan 31, 12:11 PM (EDT)
Capitalization
419.53M
28 days until earnings call
Ad is loading...

QURE vs ZVRA

Header iconQURE vs ZVRA Comparison
Open Charts QURE vs ZVRABanner chart's image
uniQure
Price$15.87
Change+$0.08 (+0.51%)
Volume$300
Capitalization814.39M
Zevra Therapeutics
Price$8.10
Change+$0.08 (+1.00%)
Volume$100
Capitalization419.53M
QURE vs ZVRA Comparison Chart
Loading...
QURE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
QURE vs. ZVRA commentary
Jan 31, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is QURE is a Buy and ZVRA is a Buy.

Ad is loading...
COMPARISON
Comparison
Jan 31, 2025
Stock price -- (QURE: $15.79 vs. ZVRA: $8.02)
Brand notoriety: QURE and ZVRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: QURE: 34% vs. ZVRA: 191%
Market capitalization -- QURE: $814.39M vs. ZVRA: $419.53M
QURE [@Biotechnology] is valued at $814.39M. ZVRA’s [@Biotechnology] market capitalization is $419.53M. The market cap for tickers in the [@Biotechnology] industry ranges from $379.55B to $0. The average market capitalization across the [@Biotechnology] industry is $2.47B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

QURE’s FA Score shows that 0 FA rating(s) are green whileZVRA’s FA Score has 1 green FA rating(s).

  • QURE’s FA Score: 0 green, 5 red.
  • ZVRA’s FA Score: 1 green, 4 red.
According to our system of comparison, ZVRA is a better buy in the long-term than QURE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

QURE’s TA Score shows that 4 TA indicator(s) are bullish while ZVRA’s TA Score has 4 bullish TA indicator(s).

  • QURE’s TA Score: 4 bullish, 4 bearish.
  • ZVRA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both QURE and ZVRA are a good buy in the short-term.

Price Growth

QURE (@Biotechnology) experienced а -0.25% price change this week, while ZVRA (@Biotechnology) price change was -0.99% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.84%. For the same industry, the average monthly price growth was +1.79%, and the average quarterly price growth was +5.50%.

Reported Earning Dates

QURE is expected to report earnings on May 05, 2025.

ZVRA is expected to report earnings on May 20, 2025.

Industries' Descriptions

@Biotechnology (-0.84% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
QURE($814M) has a higher market cap than ZVRA($420M). ZVRA YTD gains are higher at: -3.837 vs. QURE (-10.589). ZVRA has higher annual earnings (EBITDA): -78.22M vs. QURE (-157.84M). QURE has more cash in the bank: 435M vs. ZVRA (89.4M). ZVRA has less debt than QURE: ZVRA (59.9M) vs QURE (67.6M). QURE has higher revenues than ZVRA: QURE (28.6M) vs ZVRA (24.5M).
QUREZVRAQURE / ZVRA
Capitalization814M420M194%
EBITDA-157.84M-78.22M202%
Gain YTD-10.589-3.837276%
P/E RatioN/AN/A-
Revenue28.6M24.5M117%
Total Cash435M89.4M487%
Total Debt67.6M59.9M113%
FUNDAMENTALS RATINGS
QURE vs ZVRA: Fundamental Ratings
QURE
ZVRA
OUTLOOK RATING
1..100
67
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
82
Overvalued
PROFIT vs RISK RATING
1..100
10088
SMR RATING
1..100
9999
PRICE GROWTH RATING
1..100
3548
P/E GROWTH RATING
1..100
9229
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

QURE's Valuation (76) in the Biotechnology industry is in the same range as ZVRA (82) in the null industry. This means that QURE’s stock grew similarly to ZVRA’s over the last 12 months.

ZVRA's Profit vs Risk Rating (88) in the null industry is in the same range as QURE (100) in the Biotechnology industry. This means that ZVRA’s stock grew similarly to QURE’s over the last 12 months.

ZVRA's SMR Rating (99) in the null industry is in the same range as QURE (99) in the Biotechnology industry. This means that ZVRA’s stock grew similarly to QURE’s over the last 12 months.

QURE's Price Growth Rating (35) in the Biotechnology industry is in the same range as ZVRA (48) in the null industry. This means that QURE’s stock grew similarly to ZVRA’s over the last 12 months.

ZVRA's P/E Growth Rating (29) in the null industry is somewhat better than the same rating for QURE (92) in the Biotechnology industry. This means that ZVRA’s stock grew somewhat faster than QURE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
QUREZVRA
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
79%
Momentum
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
80%
MACD
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
78%
Advances
ODDS (%)
Bullish Trend 30 days ago
74%
Bullish Trend 30 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 8 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
68%
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
73%
Bearish Trend 3 days ago
87%
View a ticker or compare two or three
Ad is loading...
QURE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
UBVAX84.601.11
+1.33%
Undiscovered Managers Behavioral Val A
VCIGX13.060.08
+0.62%
VALIC Company I Dividend Value
DLACX15.550.07
+0.45%
BNY Mellon Large Cap Equity Y
FDEQX69.41N/A
N/A
Fidelity Disciplined Equity
STRGX59.37N/A
N/A
Sterling Capital MdCp Relatv Val Instl

ZVRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZVRA has been loosely correlated with CRNX. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if ZVRA jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZVRA
1D Price
Change %
ZVRA100%
+2.04%
CRNX - ZVRA
34%
Loosely correlated
+2.23%
KYMR - ZVRA
33%
Loosely correlated
+2.66%
AXON - ZVRA
33%
Loosely correlated
+2.10%
ATXS - ZVRA
33%
Poorly correlated
+0.40%
QURE - ZVRA
33%
Poorly correlated
+3.61%
More